Protara Therapeutics, Inc. (TARA): R&D Expense
$42.63M
Year ended 2025-12-31
$53.23M
Trailing 12 months to 2026-06-30
+36.4%
3-year compound annual growth
+28.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.63M | +34.5% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $31.70M | +26.9% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $24.99M | +48.7% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $16.81M | -20.3% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $21.09M | +76.0% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $11.98M | +209.0% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $3.88M | n/c | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $11.85M | -45.4% | 2020-03-20, From 2018-01-01 |
| 2017-12-31 | $21.69M | +14.9% | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $18.87M | +52.4% | 2019-03-13, From 2016-01-01 |
| 2015-12-31 | $12.38M | +92.5% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $6.43M | +61.0% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $3.99M | -32.4% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $5.91M | n/a | 2015-03-20, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $42.63M | +34.5% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $24.74M | +109.0% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $55.97M | +32.2% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $94.48M | +146.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $176.06M | -12.4% |
Compare TARA, TIL, CMPX, MGX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗